[{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"CHIESI USA INC \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"CHIESI USA INC \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Not Applicable"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Transcend-peptide","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CHIESI USA INC","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"CHIESI USA INC \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"CHIESI USA INC \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Beclomethasone Dipropionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Group \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Bayer"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Chiesi Global Rare Diseases"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"mRNA Therapeutics","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Chiesi Group","amount2":0.42999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Swixx BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Amryt Pharma \/ Amryt","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Amryt"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enzyme replacement therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Chiesi Group","amount2":0.14999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Medison Pharma"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pressurised metered dose inhaler","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Solution for Injection","sponsorNew":"Amryt Pharma \/ Amryt","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Amryt"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mannitol API","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for inhalation","sponsorNew":"CHIESI USA INC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CHIESI USA INC \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Solution for Injection","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pressurized metered-dose inhaler","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiasma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Amryt Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Amryt Pharma"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Chiesi Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Chiesi Farmaceutici"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Allinaire Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Anti-EMAP II Monoclonal Antibody","moa":"EMAP-II","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Group \/ Chiesi Farmaceutici","highestDevelopmentStatusID":"4","companyTruncated":"Chiesi Group \/ Chiesi Farmaceutici"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cangrelor","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CHIESI USA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CHIESI USA INC \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Birch Bark Extract","moa":"Keratinocytes","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Birch Bark Extract","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Metreleptin","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lomitapide","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Oleogel-S10","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":1.48,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":1.48,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Chiesi Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Pharma \/ Chiesi Farmaceutici"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Velmanase Alfa-tycv","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Affibody","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Chiesi Group","amount2":0.20999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deferiprone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Oleogel-S10","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chiesi Group","amount2":1.48,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":1.48,"dosageForm":"Gel","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa-iwxj","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Chiesi Global Rare Diseases"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Idebenone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HSK31858","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Oak Hill Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Mecasermin Rinfabate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Metreleptin","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Birch Triterpenes","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Seralutinib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Chiesi Group","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.33000000000000002,"dosageForm":"Powder In Capsule","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Oak Hill Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mecasermin Rinfabate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tanimilast","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Global Rare Diseases \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Chiesi Group
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
